Tuesday, August 18 , 2026 | 5:30 – 7:00 PM EST
7239 Woodmont Ave, Bethesda, MD 20814
MedHive: Collective Clinical Knowledge Advancing Patient Care
Earn up to 1.0 ACCME, ABIM MOC, AAPA, ANCC, ILNA, IPCE credit/point
Join us August 18th, from 5:30-7:00 PM EST for a free CME dinner event and be part of an interactive, community-focused discussion on real-world experiences and challenges in adjuvant CDK4/6 therapy for HR+ HER2- Breast Cancer.
This MedHive™ educational initiative focuses on empowering oncology nurses, NPs, and APCs to deliver personalized, evidence-based care for patients with high-risk HR+, HER2- early breast cancer. Through case-based learning and expert insights, participants will strengthen skills in recurrence risk assessment, adverse event monitoring and management (including neutropenia, GI toxicities, and ILD/pneumonitis), dose adjustment principles, and nursing-led interventions that promote long-term adherence and persistence—with downloadable quick-reference tools to reinforce real-world application.
This activity is designed for APCs—i.e., NPs and PAs—oncology nurses, and oncologists who treat HR+ HER2- EBC.
After completing this activity, the participant should be better able to:
Incorporate clinical evidence on CDK4/6 inhibitor-containing adjuvant therapy into treatment plans for patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
Develop supportive approaches to proactively monitor and mitigate adverse events (AEs) associated with CDK4/6 inhibitor-containing regimens in patients with HR+, HER2- EBC
Implement multidisciplinary strategies to improve patient adherence and persistence to adjuvant CDK4/6 inhibitor therapies, including patient-centered nursing approaches
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.
ILNA
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
In the following ILNA subject areas (maximum of 1 ILNA point can be claimed):
Nursing Practice (CBCN); Oncology Nursing Practice (OCN); Treatment (AOCNP, CBCN, CPHON, OCN, ROCN)
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
MIPS
Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Support Statement
This activity is supported by an educational grant from Lilly.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Rachel M. Layman, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Biotheryx, Boundless Bio, Celcuity, Eli Lilly, Novartis
Research Funding/Support: Accutar Biotechnology, Arvinas, Biotheryx, Celcuity, Eli Lilly, Novartis, Pfizer, Puma
Planner/Presenter
Aditya Bardia, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Alyssum, Bristol Myer Squibb, Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer, Sanofi, Vyome
Research Funding/Support: Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, OnKure, Pfizer, Sanofi
Planner/Presenter
Jamie L. Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor (all have ended): AstraZeneca, Clinical Education Alliance, Eli Lilly, HorizonCME, MJH Life Sciences, Novartis, OncLive, PeerView Institute, Research To Practice, Sermonix, Stemline Therapeutics
Planner/Presenter
Kristi K. Orbaugh, MSN, NP, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speaker: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Pfizer, Sanofi, Sobi, Stemline
Planner/Presenter
Kimberly Podsada, MSN, NP-C, CNS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AstraZeneca, Daiichi Sankyo, Gilead, Pfizer
Patient Voice
Alicia Lagendijk, BSN RN, CBCN, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Gregory Carbonetti, PhD, has a financial interest/relationship or affiliation in the form of:
Other: Artelo Biosciences (patent payment).
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
This activity is supported by an educational grant from Lilly.